Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Searching for New Pathways and Treatments for Head and Neck Squamous Cell Carcinoma

December 27th 2012

Scientists now know a lot more about the genetic landscape of head and neck cancer and hope that eventually this knowledge will lead the way to new therapies.

Low-Dose Radioiodine Ablation Is Effective Treatment for Thyroid Cancer

December 11th 2012

Low-dose radioiodine ablation with thyrotropin alfa is as effective as high-dose radioiodine ablation in patients with differentiated thyroid cancer and is safer.

FDA Approves Cabozantinib for Medullary Thyroid Cancer

November 29th 2012

The FDA approved cabozantinib, a multi-targeted tyrosine kinase inhibitor, for the treatment of metastatic medullary thyroid cancer.

Pazopanib and Cabozantinib Explored in Thyroid Cancer

October 30th 2012

Despite the fact that pazopanib and cabozantinib are not yet approved, researchers are already trying to determine the best way to integrate them into existing treatment regimens.

Dr. Sherman Discusses MEK Inhibitors for Thyroid Cancer

October 22nd 2012

Steven I. Sherman, MD, from MD Anderson Cancer Center, discusses the clinical interest in MEK inhibitors for thyroid cancer and a broad range of other tumors that signal through the MAP kinase pathway.

Dr. Cohen on the Cabozantinib Dosage and Tolerability

October 4th 2012

Ezra Cohen, MD, from the University of Chicago Medical Center, discusses the impact of cabozantinib's dose size on tolerability.

Dr. Sippel Explains Thyroid Cancer Risk Factors

October 2nd 2012

Rebecca S. Sippel, MD, from University of Wisconsin, explains the need for added screening for those at high-risk of developing thyroid cancer.

Dr. Ezra Cohen on the Pharmacokinetics of Cabozantinib

September 30th 2012

Ezra E.W. Cohen, MD, from the University of Chicago Medical Center, on the pharmacokinetics and efficacy of cabozantinib for medullary thyroid cancer.

Dr. Sherman on Sequencing Cabozantinib and Vandetanib

September 28th 2012

Dr. Eric Sherman, Memorial Sloan-Kettering Cancer Center, on the optimal sequencing of cabozantinib and vandetanib for patients with medullary thyroid cancer.

Multikinase Inhibitor Prolongs Progression-Free Survival in MTC

September 25th 2012

Cabozantinib significantly prolonged progression-free survival in medullary thyroid cancer compared with placebo among patients with radiographically confirmed progressive disease at study onset.

Photos From the American Thyroid Association Annual Meeting

September 25th 2012

Photos from the 82nd Annual Meeting of the American Thyroid Association held in Quebec City, Canada, on September 19-23, 2012.

Dr. Sippel on the Importance of the Initial Surgery for MTC

September 25th 2012

Rebecca S. Sippel, MD, from the University of Wisconsin, discusses the importance of the initial surgery for patients with medullary thyroid cancer on outcomes.

Panels of Molecular Markers Improve Diagnosis of Thyroid Cancer

September 24th 2012

The application of molecular markers is already significantly improving the diagnosis of thyroid cancer and broader application could help prevent unnecessary surgeries to confirm the diagnosis.

BRAF Mutational Status in Papillary Microcarcinoma: Diagnostic and Prognostic Potential

September 24th 2012

Four histopathologic features of papillary microcarcinoma help predict how aggressive the tumor will be and subsequently how aggressive treatment must be to prevent its spread.

Dr. Haugen Describes the 82nd Annual ATA Meeting

September 21st 2012

Dr. Bryan Haugen, from University of Colorado School of Medicine, Describes the 82nd Annual Meeting of the American Thyroid Association.

Dr. Nikiforov on Molecular Testing of Thyroid Nodules

September 21st 2012

Dr. Yuri Nikiforov, from the University of Pittsburgh, on Molecular Testing to Diagnose Cancerous Thyroid Nodules.

Blanket Approach to RAI in PTC Patients May Not Be Necessary

September 21st 2012

A blanket approach to the use of radioactive iodine may not be necessary in many patients with papillary thyroid cancer provided they undergo expert total thyroidectomy first.

Disease Stabilization Now Possible in Metastatic MTC With Targeted Therapies

September 21st 2012

The availability of molecular agents that target oncogenic signaling pathways now offers the possibility of achieving disease stabilization in a proportion of patients with metastatic medullary thyroid cancer.

Initial Operation to Remove Medullary Thyroid Cancer Best Chance for Cure

September 21st 2012

The initial surgical procedure performed for the management of medullary thyroid cancer is the best chance surgeons have for a cure.

Study Will Evaluate Panitumumab Regimen in Advanced SCCHN

September 7th 2012

Canadian researchers are investigating standard fractionation radiotherapy with concurrent high-dose cisplatin versus accelerated fractionation radiotherapy with panitumumab in locally SCCHN.